# A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a

> **NCT01724021** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 743 (actual)

## Conditions studied

- Diffuse Large B-Cell Lymphoma, Non-Hodgkin's Lymphoma

## Interventions

- **DRUG:** Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone/Prednisolone (CHOP)
- **DRUG:** Cyclophosphamide, Vincristine, Prednisone/Prednisolone (CVP)
- **DRUG:** Bendamustine
- **DRUG:** Rituximab
- **DRUG:** Rituximab
- **DRUG:** Rituximab
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT01724021
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12
- **Primary completion:** 2015-01
- **Final completion:** 2015-01
- **Target enrollment:** 743 (ACTUAL)
- **Last updated:** 2018-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01724021

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01724021, "A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT01724021. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*